Navigation Links
AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
Date:1/8/2009

TUSTIN, Calif., Jan. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a vertically integrated pharmaceutical company with operations in China and the U.S., announced today it has revised its 2009 Performance and Equity Incentive Compensation Plan for senior management and employees.

Under the terms of the Plan, AMDL has transitioned from a "discretionary cash and options-based bonus plan" to a performance-based, stock and cash incentive plan. Incentives are based on successfully achieving financial targets established by AMDL's Board of Directors.

Plan highlights include:

  • Performance based incentive awards
  • Board-determined quarterly income performance targets
  • Limited cash bonus awards
  • Reaffirmation of AMDL's commitment to not issue discretionary incentive awards

According to Mr. Michael Boswell, independent board member and Chairman of AMDL's Compensation and Audit Committees, "We have made a deliberate decision to establish a more structured compensation plan that directly links our executive and employee compensation to Company performance. In establishing this new plan, we are creating stronger alignment between the interests of our management team, employees, and investors. We feel the modifications made support AMDL's long-term success."

Under AMDL's 2009 Performance and Equity Incentive Compensation Plan, all stock granted to senior executives and employees as incentive compensation will be scheduled to vest only if the Company's meets its strategic goals and specific financial performance targets. AMDL's Board of Directors and Compensation Committee have reviewed and approved the performance targets and Plan outlined above. Detailed information on this revised Plan can be found in AMDL's Form 8-K filed with the Securities and Exchange Commission.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206. 310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
2. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
3. Ambulatory Services of America, Inc. Completes Purchase of Majority Interest in Rosa of Georgia, LLC
4. Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
5. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
6. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
7. Blue Cross and Blue Shield of Florida Completes Acquisition of Florida Health Care Plans
8. Hard To Treat Diseases (HTDS) Completes E Europe Merger
9. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Smart Financial Credit Union Completes Key FCU Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. ... Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at ... Maisel, founder of Retina Group of New York , is a Board ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... comprehensive treatment for eating disorders, is opening a brand new child and adolescent ... ages 8-17 and their families with even more specialized eating disorder treatment and ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management and ... Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute ... of the Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive ...
(Date:5/26/2016)... ... ... On May 23rd during the National Eye Institute’s “Healthy Vision Month”, Sharon ... honored by Ashram, Inc. as the world’s foremost water visionary. , “Sharon Kleyne is ... the Nile to fill their red clay pots with life-sustaining water.” Said Ashram co-founder ...
(Date:5/26/2016)... ... 2016 , ... Saint Francis Hospital & Medical Center has ... have paid off. Since implementation of these efforts, surgical errors and readmissions ... patient experiences and reduce costly complications. Since implementation in 2011, safety efforts have: ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
Breaking Medicine Technology: